Quality-of-life (QOL) outcomes vary widely for patients receiving first-line treatment for chronic lymphocytic leukemia (CLL) ...

Experts discuss the comparative efficacy of sonrotoclax plus zanubrutinib vs venetoclax in chronic lymphocytic leukemia ...

The long-term safety of ibrutinib was proven in patients with newly diagnosed or relapsed or refractory (R/R) chronic ...

EBBH-2024 is under clinical development by Essen Biotech and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL).

AT-19 is under clinical development by Shanghai YaKe Biotechnology and currently in Phase II for Chronic Lymphocytic Leukemia (CLL).

Medically reviewed by Doru Paul, MD Leukemia is a cancer of the blood-forming tissues that often develops in the bone marrow.

During the 66th American Society of Hematology Annual Meeting and Exposition, investigators revealed early-phase 1 data evaluating various BTK degraders that leverage different strategies to overcome ...

No writing assistance was utilized in the production of this manuscript. High-risk chronic lymphocytic leukemia (CLL) has a very poor prognosis with a median overall survival of 1–2 years in ...

Chronic lymphocytic leukemia (CLL) is a cancer of a white blood cell group called a B lymphocytes. It starts in the bone marrow tissue where these B cells are formed. While doctors aren't exactly sure ...

Single agent: 55% overall response rate in untreated chronic lymphocytic leukemia (CLL ... and a corticosteroid 30–120 min prior to treatment.

Changes in Blood Cell Production Over the Lifetime Could Impact Leukemia Outcomes Dec ... human lifetime could have implications for the treatment of acute myeloid leukemia and ...